Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Spine biologics industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Product trends
2.1.4 Surgery type trends
2.1.5 End-user trends
Chapter 3 Spine Biologics Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing geriatric population
3.2.1.2 Increasing prevalence of spine deformities
3.2.1.3 Increasing awareness and patient preference for minimally invasive procedures
3.2.1.4 Technological advancements in spine biologics
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment cost
3.2.2.2 Stringent regulatory requirements for approval of biologics
3.2.2.3 Limited reimbursement policies
3.2.2.4 Availability of alternative treatment options to spine surgeries
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By surgery type
3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
3.8 Reimbursement scenario
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Spine Biologics Market Estimates and Forecast, By Product (USD Million)
5.1 Key trends, by product
5.2 Bone grafts
5.2.1 Allografts
5.2.2 Autografts
5.3 Bone graft substitutes
5.3.1 Demineralized bone matrix
5.3.2 Synthetic bone grafts
5.3.3 Bone morphogenetic proteins
5.4 Platelet rich plasma
5.5 Bone marrow aspirate therapy
5.6 Other products
Chapter 6 Spine Biologics Market Estimates and Forecast, By Surgery Type (USD Million)
6.1 Key trends, by surgery type
6.2 Anterior cervical discectomy and fusion (ACDF)
6.3 Posterior lumbar interbody fusion (PLIF)
6.4 Transforaminal lumbar interbody fusion (TLIF)
6.5 Anterior lumbar interbody fusion (ALIF)
6.6 Lateral lumbar interbody fusion (LLIF)
6.7 Other surgery types
Chapter 7 Spine Biologics Market Estimates and Forecast, By End-User (USD Million)
7.1 Key trends, by end-user
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end-users
Chapter 8 Spine Biologics Market Estimates and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Switzerland
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Zimmer Biomet Holdings, Inc.
9.2 Johnson And Johnson (Depuy Synthes)
9.3 Orthofix Medical Inc.
9.4 Stryker Corporation
9.5 Arthrex, Inc.
9.6 Medtronic, Inc.
9.7 K2M, Inc.
9.8 Exactech, Inc.
9.9 Wright Medical Technology, Inc.
9.10 Nuvasive, Inc.
